Biorestorative Therapies, Inc.

BRTX Healthcare Biotechnology

Biorestorative Therapies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $359,700.00, down 10.3% from fiscal 2024. In the quarter to March 2026, revenue fell 7.20%, EPS grew 81.3% and free cash flow fell 35.3%, each against the same quarter a year earlier.

1.54 0.08 +5.48%
Market cap
$2.0M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
4/9
Altman Z
−70.97
Beneish M
−7.56
Dividend safety
n/a

Biorestorative Therapies, Inc. (BRTX) P/E ratio

Alert me on P/E ratio

Biorestorative Therapies, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
Jun 2025 0.0× —
41 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 98

P/E ratio against peers

Company P/E ratio
BRTX Biorestorative Therapies, Inc. n/m
SILO Silo Pharma, Inc. compare n/m
PPBT Purple Biotech Ltd. Sponsored ADR compare n/m
KAPA Kairos Pharma, Ltd. compare n/m
VRAX Virax Biolabs Group Limited compare n/m
CLSDQ Clearside Biomedical, Inc. compare n/m
TRVN Trevena, Inc. compare n/m
GNPX GENPREX compare 0.0×
OGEN Oragenics, Inc. compare 0.4×
Biotechnology industry median 8.5×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BRTX